Fukushima H, Yamaguchi K, Uzawa H, Kitoh M, Takemiya M, Konno T
Endocrinol Jpn. 1981 Apr;28(2):111-25. doi: 10.1507/endocrj1954.28.111.
The results of clinical endocrine and metabolic studies on a 57-year-old female with surgically and autopsy verified glucagonoma syndrome were presented. All of the clinical manifestations of glucagonoma syndrome so far reported in the literature were noted but there was no evidence indicating the presence of multiple endocrine adenomatosis. The plasma IRG level was always more than 20 times above the normal, and the IRG response to insulin and tolbutamide injection was abnormal and the results of the other endocrinological studies revealed less remarkable features, if any. The surgically removed metastatic tumor of the liver contained an enormous amount of IRG and an appreciable amount of IRI, indicating that the elevated plasma IRG was mainly of tumor origin. These results clearly indicate that in glucagonoma there is some abnormality in glucagon release from the tumor. In addition to these findings, hypocalcemia, cardiac left ventricular hypertrophy and gastrointestinal dysfunction reportedly due to hyperglucagonemia were also seen in this patient.
本文报告了一名57岁女性的临床内分泌和代谢研究结果,该患者经手术及尸检证实患有胰高血糖素瘤综合征。文献中迄今报道的胰高血糖素瘤综合征的所有临床表现均有记录,但无证据表明存在多发性内分泌腺瘤病。血浆IRG水平始终比正常水平高出20倍以上,对胰岛素和甲苯磺丁脲注射的IRG反应异常,其他内分泌学研究结果若有异常则不太显著。手术切除的肝脏转移瘤含有大量IRG和相当数量的IRI,表明血浆IRG升高主要源于肿瘤。这些结果清楚地表明,在胰高血糖素瘤中,肿瘤释放胰高血糖素存在一些异常。除这些发现外,该患者还出现了据报道由高胰高血糖素血症引起的低钙血症、心脏左心室肥厚和胃肠功能障碍。